Abstract
The c-Met/hepatocyte growth factor receptor and its family members are known to promote cancer cell migration and invasion. Signaling within and beyond this pathway contributes to the systemic spread of metastases through induction of the epithelial-mesenchymal transition, a process also implicated in mediating resistance to current anticancer therapies, including radiation. Induction of c-Met has also been observed after irradiation, suggesting that c-Met participates in radiation-induced disease progression through the epithelial-mesenchymal transition. Therefore, c-Met inhibition is an attractive target for potentially mitigating radiation resistance. This article summarizes key findings regarding crosstalk between radiotherapy and c-Met and discusses studies performed to date in which c-Met inhibition was used as a strategy to increase cellular radiosensitivity.
Copyright © 2013 American Cancer Society.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Review
MeSH terms
-
Anilides / pharmacology
-
Animals
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / pharmacology*
-
Cell Movement / radiation effects
-
DNA Damage / radiation effects
-
Epithelial-Mesenchymal Transition / drug effects
-
Epithelial-Mesenchymal Transition / radiation effects
-
Erlotinib Hydrochloride
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Neoplasm Invasiveness
-
Neoplasms / metabolism*
-
Neovascularization, Pathologic
-
Proto-Oncogene Proteins c-met / antagonists & inhibitors*
-
Proto-Oncogene Proteins c-met / metabolism*
-
Pyridines / pharmacology
-
Pyrrolidinones / pharmacology
-
Quinazolines / pharmacology
-
Quinolines / pharmacology
-
Radiation Tolerance
-
Signal Transduction / drug effects
-
Signal Transduction / radiation effects*
-
Up-Regulation
Substances
-
ARQ 197
-
Anilides
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Pyridines
-
Pyrrolidinones
-
Quinazolines
-
Quinolines
-
cabozantinib
-
rilotumumab
-
Erlotinib Hydrochloride
-
MET protein, human
-
Proto-Oncogene Proteins c-met